Rhinitis medicamentosa: Therapeutic effect of diode laser inferior turbinate reduction on nasal obstruction and decongestant abuse

American Journal of Rhinology

Volumn 22, Issue 4, 2008, Pages 433-439

  Caffier, Philipp P ^a   Frieler, Katja ^a   Scherer, Hans ^a   Sedlmaier, Benedikt ^a   Göktas, Önder ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Decongestant abuse; Diode laser; Hyperplastic inferior turbinates; Nasal congestion; Objective rhinomanometry; Outpatient inferior turbinate reduction; Rhinitis medicamentosa; Topical anesthetic; Treatment option

Indexed keywords

DECONGESTIVE AGENT;

ADOLESCENT; ADULT; AGED; ANESTHESIA; ARTICLE; CLINICAL ARTICLE; DIODE LASER INFERIOR TURBINATE REDUCTION; DISEASE RESISTANCE; DRUG ABUSE; DRUG DEPENDENCE; ENDOSCOPIC SURGERY; FEMALE; FOLLOW UP; HUMAN; INTRAOPERATIVE PERIOD; LASER SURGERY; LONG TERM CARE; MALE; MANOMETRY; NOSE AIRFLOW; NOSE OBSTRUCTION; OUTPATIENT CARE; PATIENT SATISFACTION; PERIOPERATIVE PERIOD; POSTOPERATIVE EDEMA; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE PAIN; PROSPECTIVE STUDY; RHINITIS; RHINITIS MEDICAMENTOSA; SURGICAL TECHNIQUE; VISUAL ANALOG SCALE;

ADOLESCENT; ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; LASER THERAPY; LASERS, SEMICONDUCTOR; MALE; MIDDLE AGED; NASAL DECONGESTANTS; NASAL OBSTRUCTION; OTORHINOLARYNGOLOGIC SURGICAL PROCEDURES; PATIENT SATISFACTION; PROSPECTIVE STUDIES; RHINITIS; TIME FACTORS; TREATMENT OUTCOME; TURBINATES;

EID: 51049109597     PISSN: 10506586     EISSN: None     Source Type: Journal    
DOI: 10.2500/ajr.2008.22.3199     Document Type: Article

References (30)

1. Akerlund A, and Bende M. Sustained use of xylometazoline nose drops aggravates vasomotor rhinitis. Am J Rhinol 5:157-160, 1991.
2. Graf P. Rhinitis medicamentosa: A review of causes and treatment. Treat Respir Med 4:21-29, 2005.
3. Feinberg SM, and Friedlaender S. Nasal congestion from frequent use of privine hydrochloride. JAMA 128:1095-1096, 1945.
4. Lake CF. Rhinitis medicamentosa. Proc Staff Meet Mayo Clin 21:367-371, 1946.
5. Fleece L, Mizes JS, Jolly PA, et al. Rhinitis medicamentosa. Conceptualization, incidence, and treatment. Ala J Med Sci 21:205-208, 1984.
6. Ramey JT, Bailen E, and Lockey RF. Rhinitis medicamentosa. J Investig Allergol Clin Immunol 16:148-155, 2006.
7. Toohill RJ, Lehman RH, Grossman TW, et al. Rhinitis medicamentosa. Laryngoscope 91:1614-1621, 1981.
8. Cauna N, and Cauna D. Association of nerve fibers and plasma cells in abnormal human nasal respiratory mucosa. Ann Otol Rhinol Laryngol 83:347-359, 1974.
9. Keyserling HF, Grimme JD, Camacho DL, et al. Nasal septal perforation secondary to rhinitis medicamentosa. Ear Nose Throat J 85:376-379, 2006.
10. Knipping S, Holzhausen HJ, Goetze G, et al. Rhinitis medicamentosa: Electron microscopic changes of human nasal mucosa. Otolaryngol Head Neck Surg 136:57-61, 2007.
11. Graf PM, and Hallen H. One year follow-up of patients with rhinitis medicamentosa after vasoconstrictor withdrawal. Am J Rhinol 11:67-72, 1997.
12. Tas A, Yagiz R, Yalcin O, et al. Use of mometasone furoate aqueous nasal spray in the treatment of rhinitis medicamentosa: An experimental study. Otolaryngol Head Neck Surg 132:608-612, 2005.
13. Clement PA. Committee report on standardization of rhinomanometry. Rhinology 22:151-155, 1984.
14. Gordon AS, McCaffrey TV, Kern EB, et al. Rhinomanometry for preoperative and postoperative assessment of nasal obstruction. Otolaryngol Head Neck Surg 101:20-26, 1989.
15. Baldwin RL. Rhinitis medicamentosa (an approach to treatment). J Med Assoc State Ala 47:33-35, 1975.
16. Panagou P, Loukides S, Tsipra S, et al. Evaluation of nasal patency: Comparison of patient and clinician assessments with rhinomanometry. Acta Otolaryngol 118:847-851, 1998.
17. Yaniv E, Hadar T, Shvero J, et al. Objective and subjective nasal airflow. Am J Otolaryngol 18:29-32, 1997.
18. Carney AS, Bateman ND, and Jones NS. Reliable and reproducible anterior active rhinomanometry for the assessment of unilateral nasal resistance. Clin Otolaryngol Allied Sci 25:499-503, 2000.
19. Schumacher MJ. Nasal dyspnea: The place of rhinomanometry in its objective assessment. Am J Rhinol 18:41-46, 2004.
20. Sroka R, Janda P, Killian T, et al. Comparison of long term results after Ho:YAG and diode laser treatment of hyperplastic inferior nasal turbinates. Lasers Surg Med 39:324-331, 2007.
21. Orabi AA, Sen A, Timms MS, et al. Patient satisfaction survey of outpatient-based topical local anesthetic KTP laser inferior turbinectomy: A prospective study. Am J Rhinol 21:198-202, 2007.
22. Janda P, Sroka R, Tauber S, et al. Diode laser treatment of hyperplastic inferior nasal turbinates. Lasers Surg Med 27: 129-139, 2000.
23. Chang CW, and Ries WR. Surgical treatment of the inferior turbinate: New techniques. Curr Opin Otolaryngol Head Neck Surg 12:53-57, 2004.
24. Jackson LE, and Koch RJ. Controversies in the management of inferior turbinate hypertrophy: A comprehensive review. Plast Reconstr Surg 103:300-312, 1999.
25. Janda P, Sroka R, Baumgartner R, et al. Laser treatment of hyperplastic inferior nasal turbinates: A review. Lasers Surg Med 28:404-413, 2001.
26. Morris S, Eccles R, Martez SJ, et al. An evaluation of nasal response following different treatment regimes of oxymetazoline with reference to rebound congestion. Am J Rhinol 11:109-115, 1997.
27. Graf P, and Juto JE. Sustained use of xylometazoline nasal spray shortens the decongestive response and induces rebound swelling. Rhinology 33:14-17, 1995.
28. Watanabe H, Foo TH, Djazaeri B, et al. Oxymetazoline nasal spray three times daily for four weeks in normal subjects is not associated with rebound congestion or tachyphylaxis. Rhinology 41:167-174, 2003.
29. Yoo JK, Seikaly H, and Calhoun KH. Extended use of topical nasal decongestants. Laryngoscope 107:40-43, 1997.
30. Passali D, Salerni L, Passali GC, et al. Nasal decongestants in the treatment of chronic nasal obstruction: Efficacy and safety of use. Expert Opin Drug Saf 5:783-790, 2006.